FOLD Live signals | Maximize Profits with Getagraph.com

BUY 100219 min ago

@ $13.20

Issued: 14 Feb 2024 @ 15:36

Return: -18.86%

Previous signal: Feb 14 - 09:30

Previous signal: Sell

Return: 1.62 %

Live Chart Being Loaded With Signals

Commentary (23 Apr 2024 @ 16:00):

Stats
Today's Volume	3.99M
Average Volume	3.01M
Market Cap	3.16B
EPS	$0 ( 2024-02-28 )
Next earnings date	( $-0.0600 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-21.00
ATR14	$0.0120 (0.11%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-15	Prout Samantha	Sell	7 027	Common Stock
2024-04-01	Campbell Bradley L	Buy	7 500	Common Stock
2024-04-01	Campbell Bradley L	Sell	7 500	Common Stock
2024-04-01	Campbell Bradley L	Sell	7 500	Stock Options (right to buy)
2024-03-15	Campbell Bradley L	Sell	13 375	Common Stock

INSIDER POWER
17.40
Last 100 transactions
Buy: 1 738 926 \| Sell: 1 191 633

Volume Correlation

Long: -0.45 (neutral)

Short: -0.71 (moderate negative)

Signal:(42.477) Neutral

Amicus Therapeutics Inc Correlation

10 Most Positive Correlations
FULC	0.898
SMSI	0.893
SLS	0.878
PRAX	0.86
GRFS	0.851
CNDT	0.851
NVCR	0.849
LPCN	0.848
SYBX	0.848
ICCC	0.846

10 Most Negative Correlations
TLMD	-0.848
CNCE	-0.828
TYHT	-0.812
OPCH	-0.811
EPZM	-0.809

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Amicus Therapeutics Inc Correlation - Currency/Commodity

0.68
( moderate )

0.87
( strong )

0.00
( neutral )

-0.58
( weak negative )

-0.68
( moderate negative )

0.60
( weak )

Amicus Therapeutics Inc Financials

Annual	2023
Revenue:	$399.36M
Gross Profit:	$354.16M (88.68 %)
EPS:	$-0.510

Q4	2023
Revenue:	$115.08M
Gross Profit:	$101.58M (88.26 %)
EPS:	$-0.120

Q3	2023
Revenue:	$103.50M
Gross Profit:	$93.56M (90.39 %)
EPS:	$-0.0730

Q2	2023
Revenue:	$94.50M
Gross Profit:	$85.39M (90.36 %)
EPS:	$-0.150

Financial Reports:

No articles found.

Amicus Therapeutics Inc

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.